<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352131</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000491224</org_study_id>
    <secondary_id>IMMUNO-101</secondary_id>
    <secondary_id>IMMUNO-045-5011-228</secondary_id>
    <secondary_id>UTHSC-IDD-0504</secondary_id>
    <nct_id>NCT00352131</nct_id>
    <nct_alias>NCT00625716</nct_alias>
  </id_info>
  <brief_title>Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors</brief_title>
  <official_title>A Phase I Study to Assess the Safety and Pharmacokinetics of huC242-DM4 Administered as a Single Intravenous Infusion Once Every Three Weeks to Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal&#xD;
      antibody huC242, can block tumor growth in different ways. Some block the ability of tumor&#xD;
      cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing&#xD;
      substances to them.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of maytansinoid&#xD;
      DM4-conjugated humanized monoclonal antibody huC242 in treating patients with solid tumors&#xD;
      that cannot be removed by surgery or have spread to other parts of the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of maytansinoid&#xD;
           DM4-conjugated humanized monoclonal antibody huC242 in patients with inoperable or&#xD;
           metastatic colorectal cancer, pancreatic cancer, or other solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicities of this drug in these patients.&#xD;
&#xD;
        -  Characterize the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Describe any antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, dose-escalation study.&#xD;
&#xD;
      Patients receive maytansinoid DM4-conjugated humanized monoclonal antibody huC242 IV over 4-5&#xD;
      hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of maytansinoid DM4-conjugated humanized&#xD;
      monoclonal antibody huC242 until the maximum tolerated dose (MTD) is determined. The MTD is&#xD;
      defined as the dose preceding that at which 2 of 6 patients experience dose-limiting&#xD;
      toxicity. Up to 15 patients are treated at the MTD.&#xD;
&#xD;
      Patients undergo blood collection at baseline and periodically during study for&#xD;
      pharmacokinetic studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>for the duration of the trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>for the duration of the trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>for the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>for the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>for the duration of the trial</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-colorectal Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HuC242-DM4</intervention_name>
    <description>Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.</description>
    <other_name>IMGN242</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
               -  Inoperable or metastatic disease&#xD;
&#xD;
          -  Failed standard therapy&#xD;
&#xD;
          -  Confirmed cancer antigen (CanAg) expression&#xD;
&#xD;
               -  Patients must have non-colorectal cancer or pancreatic cancer&#xD;
&#xD;
               -  Tumor must have a homogeneous pattern (i.e., staining present in &gt; 75% of tumor&#xD;
                  cells for CanAg) and are 2+ or 3+ intensity by immunohistochemistry * No known&#xD;
                  leptomeningeal disease or progressive brain disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL (transfusion allowed)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  aPTT and INR ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No hypersensitivity to agents of the same class as the study drug, humanized or&#xD;
             nonhumanized antibodies, or immunoconjugates&#xD;
&#xD;
          -  No active, uncontrolled infection&#xD;
&#xD;
          -  No hepatitis B surface antigen or hepatitis C antibody positivity&#xD;
&#xD;
          -  No history of alcoholic liver disease&#xD;
&#xD;
          -  No serious medical or psychiatric disorder that would preclude compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No other malignancy within the past 2 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or stage A low-grade&#xD;
             prostate cancer&#xD;
&#xD;
          -  No severe concurrent disease or condition that, in the opinion of the investigator,&#xD;
             would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C)&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy, immunotherapy, or hormone therapy for&#xD;
             cancer&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  No concurrent chemotherapy, other immunotherapy, radiotherapy, or other&#xD;
             investigational therapy&#xD;
&#xD;
               -  Palliative radiotherapy for related bone metastases allowed&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Mita, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Drug Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245-3217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sankhala KK, Mita AC, Ricart AD, et al.: A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-B70, 2007.</citation>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <last_update_submitted>March 16, 2010</last_update_submitted>
  <last_update_submitted_qc>March 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Operations</name_title>
    <organization>ImmunoGen, Inc.</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

